Wall Street Slides as AI Stocks Tumble Following South Korea Tech Sell-Off 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Australia Inflation Cools in May, But Core CPI Keeps RBA Rate Hike Risks Alive 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Gold Prices Rise Above $4,000 as Inflation Data and Weaker Dollar Boost Demand 
Australian Household Spending Rebounds Strongly in May as Travel and Dining Drive Consumer Growth 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
South Korea’s KOSPI Rebounds as Samsung and SK Hynix Lead Tech Stock Recovery 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
SK bioscience said on Wednesday, Nov. 23, that it has stopped the production of its COVID-19 vaccine called the SKY Covione. The biotechnology wing of the SK Group said that it is a temporary decision that was made because of the declining demand for the product.
SK bioscience mentioned that one of the reasons for the falling demand for its COVID-19 vaccine is the decreasing number of infections. Moreover, the company said the approval of requirements set by drug agencies and global health organizations have also contributed to its move to suspend the manufacturing of SKY Covione.
The spin-off of SK Chemicals, which specializes in the development and production of vaccines, named the World Health Organization (WHO) and the European Medicines Agency (EMA) as some of the groups that have set stricter rules over vaccine approvals.
In any case, despite the suspension of production, the spokesperson of SK bioscience shared that the liquid base materials being used as the main ingredient of the SKY Covione vaccines are still in production. He explained that only the final product is suspended.
"The production of finalized vaccines has been suspended, with no additional orders from the government," an official at the company told The Korea Herald. "However, the vaccine bulk is still being produced. With the bulk (finished products), we are currently waiting for the next orders of SKYCovione from the government."
The official said that the key ingredients are still being manufactured as they are needed to meet the demands once international health agencies grant their approvals. The tight regulations also restricted the exports of vaccines to developing countries such as Africa so it will take more time before the vaccines reach them.
Meanwhile, it was reported that all the unused doses of SK bioscience’s SKYCovione vaccines are likely to be discarded. This is the first ever COVID-19 vaccine that the country has produced and approved.
"The original monovalent vaccine is for people getting their first or second shots, but most Korean people have completed their first vaccination," the Korea Disease Control and Prevention Agency (KDCA) commissioner, Peck Kyong Ran, said in a statement. "Doses that we are planning to buy under an existing deal will be highly likely discarded, as well as those that we've already purchased."
Photo by: Daniel Schludi /Unsplash
